We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

114 hedge funds and large institutions have $240M invested in Sutro Biopharma in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 29

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

40% more call options, than puts

Call options by funds: $7K | Put options by funds: $5K

23% more capital invested

Capital invested by funds: $194M → $240M (+$45.4M)

6% more funds holding

Funds holding: 108 → 114 (+6)

0.07% less ownership

Funds ownership: 9.23% → 9.17% (-0.07%)

Holders
114
Holders Change
+6
Holders Change %
+5.56%
% of All Funds
1.66%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
43
Reduced
29
Closed
15
Calls
$7K
Puts
$5K
Net Calls
+$2K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.32M
2
KCM
Kynam Capital Management
New Jersey
+$1.42M
3
ACM
Aquilo Capital Management
California
+$1.33M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.12M
5
Two Sigma Investments
Two Sigma Investments
New York
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
Holocene Advisors
Holocene Advisors
New York
-$7.4M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$5.96M
3
FLSM
Frazier Life Sciences Management
California
-$2.71M
4
CS
Candriam SCA
Luxembourg
-$2.03M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$785K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Pentwater Capital Management
Florida
$1.93M +$63.5K +2,000 +5%
Morgan Stanley
27
Morgan Stanley
New York
$1.92M +$935K +29,459 +192%
ACM
28
Aquilo Capital Management
California
$1.8M +$1.33M +42,065 New
UOC
29
UBS O'Connor
Illinois
$1.62M +$153K +4,834 +15%
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$1.46M -$271K -8,541 -20%
SSA
31
Schonfeld Strategic Advisors
New York
$1.45M -$52K -1,640 -5%
Two Sigma Investments
32
Two Sigma Investments
New York
$1.39M +$1.03M +32,319 New
OM
33
Opaleye Management
Massachusetts
$1.29M +$957K +30,149 New
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$1.23M -$785K -24,745 -46%
DCM
35
DAFNA Capital Management
California
$1.21M – – –
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.13M +$3.71K +117 +0.4%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.03M +$173K +5,460 +29%
TC
38
Tejara Capital
United Kingdom
$974K +$439K +13,827 +156%
N
39
Nuveen
North Carolina
$925K +$11.4K +358 +2%
Fisher Asset Management
40
Fisher Asset Management
Washington
$843K – – –
PBM
41
Propel Bio Management
California
$837K +$619K +19,500 New
BCM
42
Bridgeway Capital Management
Texas
$730K +$540K +17,020 New
Prudential Financial
43
Prudential Financial
New Jersey
$726K +$204K +6,423 +61%
Charles Schwab
44
Charles Schwab
California
$690K – – –
EAM
45
Exome Asset Management
New York
$659K +$487K +15,360 New
Barclays
46
Barclays
United Kingdom
$567K +$220K +6,948 +111%
Citadel Advisors
47
Citadel Advisors
Florida
$566K +$264K +8,334 +172%
Ameriprise
48
Ameriprise
Minnesota
$563K +$81.4K +2,566 +24%
SAM
49
Simplify Asset Management
Nevada
$515K – – –
Man Group
50
Man Group
United Kingdom
$511K +$378K +11,909 New
1
2
3 4 5

STRO Hedge Fund Activity: Q4 2023 in Review

114 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2023, worth a combined $240M — up 23% from $194M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new STRO positions and 15 closed out — a net gain of 6 holders — while 43 added to existing stakes and 29 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.32M. The largest seller was Holocene Advisors, exiting entirely with an estimated $7.4M sold.

  • 114 institutional investors held Sutro Biopharma (STRO) as of Q4 2023, up from 108 in Q3 2023.
  • Funds reported $240M of Sutro Biopharma stock for Q4 2023, up 23% quarter-over-quarter.
  • 21 funds opened new Sutro Biopharma positions in Q4 2023 and 15 closed out, a net change of +6 holders.
  • The largest Sutro Biopharma buyer in Q4 2023 was Adage Capital Partners, an estimated $4.32M added.
  • The largest Sutro Biopharma seller in Q4 2023 was Holocene Advisors, an estimated $7.4M sold.

Based on aggregated 13F filings for Q4 2023.